Hetero
Rafael Solorio currently serves as Chief Financial Officer at Hetero since May 2024, bringing extensive experience in finance leadership from previous roles such as Finance Lead/Director at Hanesbrands Inc. from November 2019 to May 2024, and Head of Controlling GHO at Merck Group from June 2017 to November 2019. Prior positions include Finance Director at Johnson & Johnson (September 2006 - January 2016) and Manufacturing Controller at Kraft Foods (August 1998 - August 2006). Rafael Solorio holds a Master of Business Administration (MBA) from Universidad de Negocios ISEC (2003 - 2005) and a Bachelor's degree in Accounting and Finance from the same institution (1987 - 1991).
This person is not in any teams
This person is not in any offices
Hetero
4 followers
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products. Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc. Hetero has a strong global presence in over 145+ countries and focusses on making affordable medicines accessible to patients worldwide.